Table 3

Adjusted ORs for breast cancer and 95% CIs in relation to detectable PAH-DNA adduct levels stratified by menopausal status, length of residence in interview home, age at diagnosis, stage, and estrogen receptor and progesterone receptor status. Long Island Breast Cancer Study Project, 1996–1997

Stratifying factorMean (SD) PAH-DNA adduct levelsaCase, nControl, nMultivariate-adjustedb OR (95% CI)c
CasesControls
Main effect16.52 (24.18)15.14 (24.21)5754241.35 (1.01–1.81)
Menopausal status
 Premenopausal16.23 (28.10)14.19 (22.28)1801421.58 (0.94–2.66)
 Postmenopausal16.20 (21.66)15.92 (25.82)3522481.19 (0.82–1.72)
Length of residence in interview home
 <15 yr17.42 (24.14)14.30 (23.58)65491.74 (0.71–4.26)
 15+ yr16.59 (24.49)14.93 (23.15)4683441.30 (0.95–1.80)
Age at diagnosis
 <65 yr16.32 (24.02)14.12 (20.69)3703171.48 (1.05–2.09)
 65+ yr16.91 (24.56)18.74 (33.67)178901.18 (0.64–2.18)
Stage
In situ17.41 (22.66)15.14 (24.21)1294241.50 (0.93–2.42)
 Invasive16.26 (24.62)15.14 (24.21)4464241.32 (0.97–1.79)
ER and PR status
 ER+/PR+19.73 (29.93)15.14 (24.21)2184241.59 (1.06–2.37)
 ER+/PR−14.24 (25.09)15.14 (24.21)524240.92 (0.46–1.85)
 ER−/PR+17.82 (23.93)15.14 (24.21)184240.92 (0.32–2.60)
 ER−/PR−14.42 (15.66)15.14 (24.21)684241.64 (0.87–3.10)
  • a PAH-DNA adduct levels are presented untransformed.

  • b Adjusted for age at reference date (continuous), race, history of infertility problems, season of blood donation, parity (continuous), total months of lactation (continuous), BMI at age 20 (continuous), first-degree family history of breast cancer, age at first birth (centered, continuous).

  • c PAH-DNA adduct levels have been log transformed prior to logistic regression analyses (see “Materials and Methods.”).